product name SB-3CT
Description: SB-3CT is a potent, effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively. SB-3CT is a 2-[(arylsulfonyl)methyl]thiirane that achieves potent inhibition, by a thiirane-opening mechanism, of the MMP2 and MMP9 zinc metalloproteases. SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat.
References: Cancer Res. 2005 May 1;65(9):3523-6.
306.40
Formula
C15H14O3S2
CAS No.
292605-14-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 61 mg/mL (199.1 mM)
Water: <1 mg/mL
Ethanol: 10 mg/mL (32.6 mM)
Solubility (In vivo)
4% DMSO+corn oil: 10 mg/mL
Synonyms
other peoduct :
| In Vitro |
In vitro activity: SB-3CT directly inhibits bone marrow endothelial cell invasion and tubule formation in Matrigel in vitro. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In L-CI.5s T-cell lymphoma model, SB-3CT (5-50 mg/kg/d i.p.) potently inhibit liver metastasis and increases survival of mice. SB-3CT (50 mg/kg/d i.p.) inhibits human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model. In a mouse model of embolus-induced “permanent” focal cerebral ischemia, SB-3CT counteracts degradation of neuronal laminin, protects neurons from ischemic cell death, and ameliorates neurobehavioral outcomes after embolic MCA occlusion. |
| Animal model | Mouse L-CI.5s T-cell lymphoma model |
| Formulation & Dosage | Dissolved in 10% DMSO.; 50 mg/kg; i.p. injection |
| References | Cancer Res. 2005 May 1;65(9):3523-6; Int J Cancer. 2006 Jun 1;118(11):2721-6. |
